Clinical studies showed that SATB1 is overexpressed in various types of cancer such as breast cancer [7], endometrial cancer [8] and renal cell carcinoma [9], etc. Overexpression of SATB1 correlated with adverse clinical parameters and poor prognosis. This evidence concerns the gene SATB1 and endometrial cancer.